Poor Potential Coverage for 7-Valent Pneumococcal Conjugate Vaccine, Malawi by Gordon, Stephen B. et al.
Poor Potential
Coverage for 7-Valent
Pneumococcal
Conjugate Vaccine,
Malawi
Stephen B. Gordon,* Stonard Kanyanda,*
Amanda L. Walsh,* Kirsty Goddard,* 
Mas Chaponda,† Victoria Atkinson,† 
Wakisa Mulwafu,† Elizabeth M. Molyneux,† 
Ed E. Zijlstra,† Malcolm E. Molyneux,* 
and Steve M. Graham* 
Streptococcus pneumoniae infections can be prevent-
ed by using new conjugate vaccines, but these vaccines
have limited serogroup coverage. We report the first
serogrouping data from carried and invasive isolates
obtained from children and adults in Malawi. The 7-valent
vaccine would cover 41% of invasive isolates from children
and 25% from adults. A 9-valent vaccine, including types 1
and 5, would cover 66% of invasive isolates from children
and 55% from adults. 
S
treptococcus pneumoniae is the leading cause of bacte-
rial meningitis in both children and adults in Malawi, as
well as an important cause of pneumonia, bacteremia, and
death for all ages (1,2). The incidence of S. pneumoniae
was reduced in the United States and Europe after the
licensing of a 7-valent pneumococcal conjugate vaccine
(3), and the Global Alliance for Vaccines and
Immunization (available from: URL: http://www.vac-
cinealliance.org) has plans to expand the use of the vaccine
to sub-Saharan Africa (4). However, few data from the
central African region exist on which to base a pneumo-
coccal conjugate vaccination program. 
Methods
Collection of Pneumococcal Isolates
Queen Elizabeth Central Hospital, the main referral
hospital for southern Malawi, admits approximately
12,000 children and 10,000 adults per year. From 1996 to
1998, blood cultures and cerebrospinal fluid (CSF) sam-
ples were taken from patients admitted to emergency in
whom they were indicated. Guidelines suggest that blood
cultures should be taken from all febrile patients and lum-
bar puncture performed if two of three clinical findings
(headache, fever, and altered consciousness) indicate
meningitis. S. pneumoniae were identified from these sam-
ples by using colony morphology on blood agar, optochin
sensitivity, and Gram stain. All S. pneumoniae isolates col-
lected from these samples were stored in bead and broth
bacterial cryopreservers (Prolab Diagnostics, Ontario,
Canada) at –80°C for serogrouping at a later date. 
Carriage Study
From March to July 1998, we collected samples from
250 children and 500 adults by using a single posterior
nasal swab, with a sterile cotton swab dipped in saline. The
swab was then directly rolled on to a sheep blood agar
plate and incubated overnight. Colony subcultures with
typical morphologic findings were placed on a second
blood agar plate with an optochin disc and cultured at 35°C
and 5% CO2. After 18–24 hours, colonies selected on the
basis of typical colony morphologic findings and Optochin
sensitivity were stored at –80°C.
Serogrouping
Stored isolates were recultured for typing by using both
sheep blood agar plates and enrichment broth (brain heart
infusion and Vitox [Oxoid, Basingstoke, U.K.]).
Pneumococcal serogrouping was performed with the
Quellung reaction with a standard technique (5) and a
diagnostic kit from Statens Serum Institut (SSI),
Copenhagen, Denmark. This diagnostic kit uses a matrix to
group pneumococci covered by the 23-valent pneumococ-
cal vaccine but does not allow typing of pneumococci to
the 90 described capsular types. All serogrouping was per-
formed by two investigators (S.B.G. was trained at the
World Health Organization [WHO] Pneumococcal
Reference Laboratory at SSI, Copenhagen; he trained S.K.
who sent a set of serogrouped isolates and isolates that
could not be typed by kit to SSI for confirmation of accu-
rate technique). 
Results
Atotal of 628 invasive pneumococcal isolates were col-
lected from the emergency pediatric and medical service.
These isolates consisted of 114 pediatric blood cultures,
206 pediatric CSF samples, 208 adult blood cultures, and
100 adult CSF samples. In the carriage study, 105 isolates
were collected from 250 children (42% carriage) and 54
isolates were collected from 500 adults (10.8% carriage).
Because of a storage accident, some isolates (predominant-
ly pediatric CSF samples) thawed and were not recovered.
The total isolates available for serogrouping was 428
(Figure). 
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Types 1 and 5 accounted for 27% and 23% of the isolates
from pediatric blood and CSF samples, respectively, and
29% and 31% of the isolates from adult blood and CSF
samples, respectively. The potential coverage of the 7-
valent conjugate vaccine, which excludes these types, was
poor. A high percentage of non–23-valent vaccine type
pneumococci existed in adult invasive isolates (35%). A
sample of 10 such isolates was sent to the WHO
Pneumococcal Reference Laboratory for confirmation of
serogrouping. Five strains could not be typed or were
acapsulate (“rough”) pneumococci, three were not vaccine
strains (28F, 16F, and 31), one was S. oralis, and one was
a misclassified type 7C.
Discussion
These data are the only recent pneumococcal
serogrouping data from children and adults available in
this region of Africa. As expected, the data showed high
rates of pneumococcal carriage in children and lower rates
in adults. The pattern of serogroups showed higher rates of
types 1 and 5 than that reported from the United States and
Europe. The pattern seen in Malawi is similar to that from
West Africa (6). A higher incidence of non–23-valent vac-
cine type pneumococci occurred in our study compared
with the incidence in other studies, particularly in our adult
isolates; this finding may reflect the high incidence of HIV
seropositivity in our population. Recent data from South
Africa indicate an increase of typical pediatric carried
types (non–23-valent types), causing disease in HIV-
infected adults (7). Other recent data are available from
coastal Kenya (8), but both of these datasets represent a
different population, in terms of ethnic diversity, geo-
graphic separation, and HIV seroprevalence. 
The potential coverage of invasive pneumococcal iso-
lates offered by the available 7-valent vaccine was poor in
Malawi. Previous estimates have suggested that conjugate
vaccine coverage in this region would be 70% to 88% (9).
We tested a large number of isolates; although some were
lost before serogrouping could be performed, the lost iso-
lates probably did not alter the serogroup distribution in
our study. In 1980 before the 23-valent polysaccharide
vaccine was formulated, serogroups 1 and 5 were consid-
ered essential in vaccines for use in Africa (6); a 9-valent
vaccine, including serogroups 1 and 5, is already under
trial in the Gambia and South Africa (4). Our study indi-
cates that the inclusion of types 1 and 5 will make a sub-
stantial difference to the efficacy of the vaccine in Malawi.
Alternatively, protein vaccines may have high efficacy
against a still wider range of pneumococci.
Antibiotic use is very low in Malawi compared with
other parts of the world, and Pneumocystis carinii pneu-
monia prophylaxis is almost unknown because of the lack
of healthcare provision. Very low rates of pneumococcal
resistance to penicillin (14%), chloramphenicol (24%),
and erythromycin (1%) exist in Malawi (10). However,
resistance to co-trimoxazole is high (94%) because of the
use of sulphamethoxazole-pryrimethamine as firstline
anti-malarial drug therapies (11). We were not able to com-
pare the incidence of different serotypes between resistant
and nonresistant strains because of the small numbers of
penicillin-, chloramphenicol-, or erythromycin-resistant
isolates and the small number of cotrimoxazole-sensitive
isolates.
HIVinfection is a particular problem in Malawi, both in
adults and children. An estimated 18% of pediatric hospi-
tal patients, 72% of adult hospital patients, and 95% of
adults with invasive pneumococcal disease are seroposi-
tive for HIV in Blantyre, Malawi (12). Conjugate vaccine
is safe and immunogenic in HIV-infected persons (13), and
conjugate vaccine was shown to be effective in HIV-infect-
ed children, albeit at lower levels than in non–HIV-infect-
ed children (14). The vaccine coverage of pneumococcal
types, vaccine percentage efficacy, and stage of HIV dis-
ease in vaccine recipients are critical determinants of
whether this strategy will be of value in adults. However,
exposure to children carrying pneumococci is a known risk
factor for invasive pneumococcal disease in adults (4).
Therefore, reduced carriage of disease-causing pneumo-
coccal strains in children could reduce the adult incidence
of invasive pneumococcal disease in this population.
Pneumococcal serogroups will continue to be monitored in
disease-causing isolates so that vaccine can be implement-
ed in a timely manner.
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